Efficacy and safety of cavernous sinus medial wall resection in pituitary adenoma surgery: a systematic review and a single-arm meta-analysis
- PMID: 37382779
- DOI: 10.1007/s11102-023-01332-5
Efficacy and safety of cavernous sinus medial wall resection in pituitary adenoma surgery: a systematic review and a single-arm meta-analysis
Abstract
Introduction: Pituitary adenomas, benign tumors, can lower quality of life. Pituitary adenomas that invade the medial wall and cavernous sinus (CS) indicate tumor recurrence and partial surgical excision. Despite the cavernous sinus's complexity and risks, new research has improved the surgical procedure and made excision safer. This comprehensive review and single-arm meta-analysis evaluates endocrinological remission and resection rates in pituitary adenomas to determine the benefits and risks of MWCS resection.
Methods: Databases were systematically searched for studies documenting the resection of the medial wall of the cavernous sinus. The primary outcome was endocrinological remission in patients who underwent resection of the MWCS.
Results: Eight studies were included in the final analysis. The pooled proportion of endocrinological remission (ER) was 63.3%. The excision of MWCS pooled a gross total resection (GTR) proportion of 72.9%. Finally, ICA injury attained a pooled ratio of 0.5%, indicating minimal morbidity in the procedure.
Conclusion: The cavernous sinus was ruled out, proving the MWCS excision is safe. Limiting population selection to Knosp 3A or lower enhanced GTR frequencies and lowered recurrence, according to subgroup analyses. This meta-analysis shows that MWCS resection can be a beneficial treatment option for pituitary tumors, when there is no macroscopic medial wall invasion and careful patient selection is done, especially for GH- and ACTH-producing tumors that can cause life-threatening metabolic changes.
Keywords: Endocrinological remission; Endoscopic endonasal; Medial wall of cavernous sinus; Pituitary adenoma; Recurrence.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- Tritos NA, Miller KK (2023) Diagnosis and management of pituitary adenomas: a review. JAMA 329(16):1386–1398. https://doi.org/10.1001/jama.2023.5444 - DOI - PubMed
-
- Shlomo Melmed and others (2022) Clinical biology of the pituitary adenoma. Endocr Rev 43(6):1003–1037. https://doi.org/10.1210/endrev/bnac010 - DOI
-
- Varlamov EV, McCartney S, Fleseriu M (2019) Functioning pituitary adenomas - current treatment options and emerging medical therapies. Eur Endocrinol 15(1):30–40. https://doi.org/10.17925/EE.2019.15.1.30 - DOI - PubMed - PMC
-
- Daly AF, Beckers A (2020) The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am 49(3):347–355. https://doi.org/10.1016/j.ecl.2020.04.002 - DOI - PubMed
-
- van Trigt VR, Pelsma ICM, Biermasz NR (2023) Patient-reported outcomes in refractory hormone-producing pituitary adenomas: an unmet need. Pituitary. https://doi.org/10.1007/s11102-023-01309-4 - DOI - PubMed - PMC
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous